QUEBEC CITY, Nov. 21 /CNW Telbec/ - AEterna Zentaris Inc. (TSX: AEZ;
NASDAQ: AEZS) today announced it has completed enrollment of 144 patients for
a Phase II trial with ozarelix (D-63153) in benign prostatic hyperplasia
(BPH), more than four months ahead of schedule. The randomized, placebo-
controlled multi-center clinical trial is designed to evaluate both objective
parameters, such as improvement in urine flow and shrinkage of the prostate
volume, as well as various symptoms of BPH over a period of several months.
The trial is being conducted in Europe with the collaboration of Spectrum
Pharmaceuticals Inc. (NASDAQ: SPPI) and results are expected to be disclosed
during the second half of 2006.
